ASH 2023 | KdD vs Kd for R/R MM: renal subgroup analysis from CANDOR
Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, summarizes the data coming from a subgroup analysis of the CANDOR study (NCT03158688)- a Phase III study comparing carfilzomib, daratumumab, and dexamethasone (KdD) versus carfilzomib and dexamethasone (Kd) for relapsed/refractory (R/R) multiple myeloma (MM). This analysis was conducted using data from patients with at least moderate renal impairment, assessed using creatinine clearance values, and showed that KdD provided a consistent clinical benefit versus Kd in terms of median progression-free survival (PFS), overall survival (OS) and overall response rate (ORR), irrespective of renal function. Safety findings were consistent with the overall population. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Amgen, AbbVie, Takeda, Beigene, BMS, GSK, Janssen, Menarini, Regeneron, Sanofi
